Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Gilead Sciences Inc GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Kite and Arcellx Announce Expansion in Strategic Partnership

Business Wire November 15, 2023

Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS

ACCESS Newswire November 14, 2023

Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research

ACCESS Newswire November 9, 2023

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire November 8, 2023

Gilead Sciences Announces Third Quarter 2023 Financial Results

Business Wire November 7, 2023

Gilead Sciences: Advancing Global Health Equity in Tropical Regions

ACCESS Newswire November 7, 2023

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Business Wire November 6, 2023

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

Business Wire November 3, 2023

Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

Business Wire November 2, 2023

Gilead's Commitment to Advancing Health Equity for Black Women and Ending the HIV Epidemic

ACCESS Newswire October 31, 2023

Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

Business Wire October 31, 2023

Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS

Business Wire October 24, 2023

New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV

Business Wire October 20, 2023

Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities

Business Wire October 19, 2023

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

Business Wire October 18, 2023

Gilead Sciences: Leading With Passion and Purpose: Sandra's Story

ACCESS Newswire October 17, 2023

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Business Wire October 17, 2023

Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

Business Wire October 16, 2023

Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023

Business Wire October 16, 2023

Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

Business Wire October 12, 2023